Shopping Cart
- Remove All
Your shopping cart is currently empty
Otelixizumab
🥰Excellent
Catalog No. T76754Cas No. 881191-44-2
Alias TRX4, TRX 4, GSK-2136525, GSK2136525, ChAglyCD3
Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases.
Otelixizumab
Otelixizumab
🥰Excellent
Catalog No. T76754Alias TRX4, TRX 4, GSK-2136525, GSK2136525, ChAglyCD3Cas No. 881191-44-2
Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $169 | In Stock | |
| 5 mg | $448 | In Stock | |
| 10 mg | $715 | In Stock | |
| 25 mg | $1,080 | In Stock | |
| 50 mg | $1,460 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreSelect Batch
Concentration:11.61 mg/mL
Purity:>95%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | Otelixizumab (ChAglyCD3) is a chimeric monoclonal antibody targeting CD3, used in research on Type 1 diabetes and autoimmune diseases. |
| In vitro | Methods: Isolated intrinsic monocyte layer (LPMC) and mucosal tissue explants were incubated with Otelixizumab for 24-48 hours. The production of inflammatory cytokines was determined by enzyme-linked immunosorbent assay. Results: Incubation of LPMC with Otelixizumab reduced the production of interferon gamma, interleukin (IL) -17A, and other inflammatory cytokines and chemokines, while increasing the production of IL-10.[1] |
| In vivo | Human CD3ε chain (nod-HUCdε) transgenic mice treated with Otelixizumab (50 μg/ day, 5 days, intravenously) experienced remission of diabetes symptoms in 47% of mice.[2] |
| Alias | TRX4, TRX 4, GSK-2136525, GSK2136525, ChAglyCD3 |
| Cas No. | 881191-44-2 |
Storage & Solubility Information
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Otelixizumab | purchase Otelixizumab | Otelixizumab cost | order Otelixizumab | Otelixizumab in vivo | Otelixizumab in vitro
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.